The Tier 1 alterations in both patients (#34 CLA and #17 CLB) consisted of gain‐of‐function PIK3CA mutations for which the targeted inhibitor alpelisib is FDA‐approved in ER‐POS, HER2 NEG breast cancer in conjunction with fulvestrant [43]. This evidence concerns the gene ERBB2 and breast carcinoma.